Get the Stockscreener App
1.13
3.42%
-0.04
Alzamend Neuro Inc stock is traded at $1.13, with a volume of 59,398.
It is down -3.42% in the last 24 hours and up +2.73% over the past month.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
See More
Previous Close:
$1.17
Open:
$1.21
24h Volume:
59,398
Relative Volume:
0.47
Market Cap:
$4.30M
Revenue:
-
Net Income/Loss:
$-7.04M
P/E Ratio:
-0.2581
EPS:
-4.3784
Net Cash Flow:
$-6.17M
1W Performance:
+10.78%
1M Performance:
+2.73%
6M Performance:
-42.35%
1Y Performance:
-68.26%
1-Day Range:
$1.11
$1.21
1-Week Range:
$1.00
$1.29
52-Week Range:
$0.84
$8.22
Alzamend Neuro Inc Stock (ALZN) Company Profile
Name
Alzamend Neuro Inc
Sector
Industry
Phone
844-722-6333
Address
480 PEACHTREE ROAD NE, SECOND FLOOR, ATLANTA
Compare ALZN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALZN
Alzamend Neuro Inc
|
1.13 | 4.45M | 0 | -7.04M | -6.17M | -4.3784 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-21 | Initiated | Ascendiant Capital Markets | Buy |
Alzamend Neuro Inc Stock (ALZN) Latest News
ALZN Q1 2026 Earnings: EPS Surpasses Estimates by Over 70%, Stock DeclinesMargin Improvement Report - Newser
TradingKey - TradingKey
How Alzamend (ALZN) handles its debt maturity schedule | Q1 2026: Earnings Beat EstimatesTop Analyst Buy Signals - newser.com
Alzamend Neuro Inc. (ALZN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
ALZN Stock Price, Quote & Chart | ALZAMEND NEURO INC (NASDAQ:ALZN) - ChartMill
Alzamend Neuro (ALZN) price target decreased by 10.71% to 25.50 - MSN
Alzamend (ALZN) Stock Swing Trade Setup (On the Radar) 2026-04-20Sector Rotation - Cổng thông tin điện tử tỉnh Lào Cai
Alzamend Neuro, Inc. 8-K Filing Details, NASDAQ Listing, and Corporate Information (April 17, 2026) - Minichart
Alzamend Neuro Shareholders Approve Governance and Capital Measures - The Globe and Mail
Shareholders of Alzamend Neuro (ALZN) approve board slate, plans and reverse split - Stock Titan
Director Milton Ault adds Alzamend Neuro (ALZN) shares in open-market buy - Stock Titan
CEO Moves: How sensitive is Alzamend Neuro Inc to inflationEarnings Overview Report & Smart Investment Allocation Tips - baoquankhu1.vn
Form PRE 14AOther preliminary proxy statements - ADVFN
Can Alzamend Neuro Inc disrupt its industryEarnings Growth Summary & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Aug Sectors: What is the dividend yield of Alzamend Neuro IncQuarterly Profit Review & Long-Term Safe Return Strategies - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE), Alzamend Neuro (ALZN) and Cardiol Therapeutics (CRDL) - The Globe and Mail
Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital - Sahm
In a 6-person study, new lithium therapy disturbed less brain chemistry - Stock Titan
Alzamend Neuro Stock Rockets On Dosing Of First Human Patient With Lithium-Delivery System AL001 In Phase II Study: Retail’s Thrilled - MSN
Hedge Fund Bets: Can Alzamend Neuro Inc disrupt its industryChart Signals & Consistent Income Trade Recommendations - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Alzamend’s AL001 meets bioequivalence in phase 2 brain trial By Investing.com - Investing.com Australia
Alzamend Neuro in Freefall: A 22% Plunge Shatters $1.93 as Panic Sets In - Bitget
Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions - Investing News Network
Alzamend’s AL001 meets bioequivalence in phase 2 brain trial - Investing.com
Across 26 brain regions, Alzamend’s lithium drug showed higher levels - Stock Titan
Alzamend Neuro Receives Nasdaq Notice Over Equity Deficiency - The Globe and Mail
Alzamend Neuro, Inc. Receives Nasdaq Delisting Notice: SEC Form 8-K Filing March 2026 - Minichart
Alzamend Neuro Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
[8-K] Alzamend Neuro, Inc. Reports Material Event - Stock Titan
Exit Recap: How sensitive is Alzamend Neuro Inc to inflationEarnings Performance Report & Free Verified High Yield Trade Plans - baoquankhu1.vn
Quarterly Recap: Will PAVM outperform during market rallies2026 Price Momentum & Short-Term High Return Strategies - baoquankhu1.vn
Alzamend initiates phase II trial of AL001 in bipolar disorder By Investing.com - Investing.com South Africa
Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital - Investing News Network
Alzamend Neuro initiates phase II clinical trial of AL001 "lithium in brain" study in patients with bipolar disorder in collaboration with Massachusetts General Hospital - marketscreener.com
Alzamend initiates phase II trial of AL001 in bipolar disorder - Investing.com
Alzamend Neuro Initiates Phase Ii Clinical Trial Of Al001 "Lithium In Brain" Study In Patients With Bipolar Disorder In Collaboration With Massachusetts General Hospital - TradingView
Alzamend Neuro, Inc. Q3 2026 Financial Results and SEC 10-Q Filing Overview - Minichart
Alzamend Neuro 10-Q: $0.00M Revenue, $(0.58) EPS Q3; $(1.89) EPS YTD - TradingView
Alzamend Neuro (NASDAQ: ALZN) posts $5.9M loss and warns on going concern - Stock Titan
Alzamend Neuro Establishes ATM Equity Offering Agreement - The Globe and Mail
Is Alzamend Neuro Inc stock a hidden gemEarnings Growth Report & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Alzamend Neuro Inc enters ATM sales agreement to sell up to $3.0 million in common stockSEC filing - marketscreener.com
Alzamend Neuro Launches $3 Million ATM Equity Program With Ascendiant Capital Markets - TradingView
Alzamend Neuro (ALZN) launches $3.0M at-the-market common stock offering - Stock Titan
Alzamend Neuro Inc expected to post a loss of $1.92 a shareEarnings Preview - TradingView
10 Health Care Stocks Moving In Monday's Pre-Market Session - Sahm
ALZN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ALZN Should I Buy - Intellectia AI
Alzamend Neuro (ALZN) to Release Quarterly Earnings on Monday - Defense World
Alzamend Neuro Inc Stock (ALZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alzamend Neuro Inc Stock (ALZN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| AULT MILTON C III | Director |
Dec 23 '25 |
Sale |
2.07 |
1,851 |
3,825 |
0 |
| Horne William B. | Director |
Dec 19 '25 |
Sale |
2.12 |
3,333 |
7,059 |
0 |
| McGrath Lynne Fahey | Director |
Oct 23 '25 |
Sale |
2.29 |
30 |
69 |
25 |
| AULT MILTON C III | Director |
Oct 08 '25 |
Sale |
2.44 |
101,394 |
247,158 |
28,657 |
| AULT MILTON C III | Director |
Oct 09 '25 |
Sale |
2.32 |
20,397 |
47,390 |
8,260 |
| AULT MILTON C III | Director |
Oct 06 '25 |
Sale |
2.45 |
82,033 |
201,268 |
26,227 |
| AULT MILTON C III | Director |
Oct 07 '25 |
Sale |
2.49 |
57,379 |
142,954 |
68,848 |
| AULT MILTON C III | Director |
Oct 03 '25 |
Sale |
2.44 |
65,903 |
160,889 |
8,260 |
| AULT MILTON C III | Director |
Oct 01 '25 |
Sale |
2.35 |
36,777 |
86,378 |
94,849 |
| AULT MILTON C III | Director |
Oct 02 '25 |
Sale |
2.39 |
20,686 |
49,522 |
74,163 |
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):